1. Home
  2. CMU vs MGNX Comparison

CMU vs MGNX Comparison

Compare CMU & MGNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo MFS Municipal Income Trust

CMU

MFS Municipal Income Trust

HOLD

Current Price

$3.52

Market Cap

88.5M

Sector

Finance

ML Signal

HOLD

Logo MacroGenics Inc.

MGNX

MacroGenics Inc.

HOLD

Current Price

$1.79

Market Cap

94.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CMU
MGNX
Founded
1987
2000
Country
United States
United States
Employees
N/A
N/A
Industry
Investment Managers
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
88.5M
94.9M
IPO Year
N/A
2013

Fundamental Metrics

Financial Performance
Metric
CMU
MGNX
Price
$3.52
$1.79
Analyst Decision
Hold
Analyst Count
0
5
Target Price
N/A
$3.20
AVG Volume (30 Days)
82.4K
1.8M
Earning Date
01-01-0001
11-12-2025
Dividend Yield
4.08%
N/A
EPS Growth
N/A
N/A
EPS
0.07
N/A
Revenue
N/A
$127,626,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$47.57
N/A
Revenue Growth
N/A
N/A
52 Week Low
$2.78
$0.99
52 Week High
$3.38
$3.55

Technical Indicators

Market Signals
Indicator
CMU
MGNX
Relative Strength Index (RSI) 62.62 65.20
Support Level $3.47 $1.54
Resistance Level $3.51 $1.89
Average True Range (ATR) 0.03 0.10
MACD 0.01 0.03
Stochastic Oscillator 94.44 71.38

Price Performance

Historical Comparison
CMU
MGNX

About CMU MFS Municipal Income Trust

Mfs High Yield Municipal Trust is a United States-based diversified, closed-end management investment company. Its investment objective is to seek high current income exempt from federal income tax. The fund invests a majority of its net assets, including assets attributable to preferred shares and borrowings for investment purposes, in tax-exempt bonds and tax-exempt notes. The company invest various top Healthcare companies, Airport, Universities (Secondary Schools), Universities (Dormitories), and many more, out of maximum revenue is gained from Healthcare Hospitals and Long Term Care.

About MGNX MacroGenics Inc.

Macrogenics Inc is a biotechnology company focused on discovering and developing antibody-based therapeutics for the treatment of cancer. Its product includes MARGENZA, which is for the treatment of adult patients with metastatic HER2-positive breast cancer. It's a pipeline of product candidates designed to target either various tumor-associated antigens or immune checkpoint molecules. The company has three proprietary product candidates in clinical development: lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4; MGC026, an ADC that targets B7-H3 and delivers a novel topoisomerase I inhibitor (TOP1i)-based linker-payload, and MGC028, an ADC that targets ADAM9 and delivers a novel TOP1i-based linker-payload.

Share on Social Networks: